Diabetes News

Topical propolis is a well-tolerated therapy for wound healing and this pilot in human DFU indicates for the first time that it may enhance wound closure in this setting when applied weekly. A multi-site randomized controlled of topical propolis now appears to be warranted in diabetic foot ulcers (Diabetes and Its Complications)

The results of this study indicate that topical application of OSM may have the potential to accelerate healing of diabetic wounds (Internal Wound Journal)

Several multidrug resistant strains were observed among the samples tested and most of these strains had the ability to elicit moderate to high levels of biofilm. The weakened immune response in diabetic individuals and synergism among pathogenic microorganisms may be critical factors that may determine the delicate balance of wound healing process (Journal of Medical Microbiology)

As ADMs increasingly become the surgeon’s method of choice in treating diabetic foot ulcers, it becomes more important to select the best-performing biological scaffold. This study shows favorable closure rates combined with a decreased time needed for complete closure when using D-ADM (Wounds)

In this review, the mechanism of EPO’s action in skin wound healing is reviewed, and its potential for treating acute and chronic skin wounds and stimulating tissue regeneration in diabetic patients is discussed (Wound Repair and Regeneration)

TcPO2= 40 mmHg was associated with diabetic foot ulcer healing, but a TcPO2= 10 mmHg was associated with failure of wound healing. We found that a cut-point of 25 mmHg was most predictive of diabetic foot ulcer healing (Journal of Wound, Ostomy and Continence Nursing)

Grafix closes three times as many wounds as standard of care – the largest relative improvement ever reported in a multi-center, randomized, controlled clinical trial for DFU (BioSpace)

Employing evidence-based guidelines, multidisciplinary teams, and institution-specific clinical pathways provides the best approach to guide clinicians through this multifaceted problem (Diabetes, Obesity and Metabolism)

The in vitro effects of CRT on these functions are consistent with CRT’s potent effects on wound healing in the diabetic mouse. These studies implicate CRT as a potential powerful topical therapeutic agent for the treatment of diabetic and other chronic wounds (Wound Repair and Regeneration)

These findings summarise all available trial evidence regarding the use of dressings to heal diabetic foot ulcers. More expensive dressings may offer no advantages in terms of healing than cheaper basic dressings (Diabetologia)

MacroCure currently manufactures and markets its lead product, CureXcell™, in Israel for hard-to-heal wound treatment. The cell therapy company has its regulatory strategy in place for market approval in North America and Europe. CureXcell™, a cell based therapy for hard to heal wounds, to restore the wound healing process (You Tube video from MacroCure)